Newron Pharmaceuticals - Evenamide set for a pivotal year
Newron Pharmaceuticals has reported results for FY23, an active period for its lead asset, evenamide, being developed for treatment-resistant...
431 Views
Newron Pharmaceuticals - Operational flexibility with new/updated financing
Newron Pharmaceuticals has announced new arrangements that offer the company improved operational flexibility. We estimate a pro forma gross cash...
456 Views
Newron Pharmaceuticals - TRS data green-lights evenamide Phase III plans
Newron has announced positive 12-month data from its Phase II extension trial (study 015) assessing evenamide in 161 patients with...
474 Views
Newron Pharmaceuticals - Key Evenamide readouts on the horizon
Newron is a Swiss Stock Exchange SIX-listed (NWRN) biopharmaceutical company focused on developing novel medicines for diseases of the central...
328 Views
Newron Pharmaceuticals - Positive readout highlights evenamide potential
Newron has announced encouraging interim six-month data from its Phase II trial (study 014/015) of evenamide in 161 patients with...
314 Views